This trial is studying magrolimab in combination with other drugs as a possible treatment for relapsed/refractory multiple myeloma. The goal is to see if it is safe and to find out what the best dose is. Another goal is to see if it is effective in treating relapsed/refractory multiple myeloma.
4 Primary · 7 Secondary · Reporting Duration: Up to 2.5 years
153 Total Participants · 8 Treatment Groups
Primary Treatment: Magrolimab · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: